CMV Infection

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration

Study Evaluating the Efficacy and Safety of Artesunate

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China

Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil

Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA

CMV-TCR-T Cells for Refractory CMV Infection After HSCT

Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response

Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation